Multiple insider selling at Aurora Cannabis (T:ACB)

Christopher Mayerson, a Subsidiary Executive, disposed of 250,000 Common Shares on a direct ownership basis at prices ranging from $2.680 to $3.250 between April 6th and 10th, 2017. This represents a $713,462 divestment of the company's shares and an account share holdings change of -10.5%.

In addition, Dale Lesack, a Subsidiary Executive, disposed of 80,000 Common Shares on a direct ownership basis at a price of $3.230 on April 10th, 2017. This represents a $258,400 divestment of the company's shares and an account share holdings change of -2.1%.

Aurora Cannabis is in the Fishing & Farming Sub Industry Group under the Consumer Non-Cyclicals Sector.

Aurora Cannabis Inc. is engaged in the production and sale of medical cannabis. The Company is engaged in the business of producing and distributing medical marijuana pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company's product types include Tetrahydrocannabinol (THC), Cannabidiole (CBD), indica, sativa and hybrid. Its product range includes BLACK TUSK 2, CHESTER, KAINE and TOWER. The Company is also focusing on other products, which will be available for sale either as pre-milled buds (Borealis Blends) or as whole buds, including ANDROMEDA 2, HAIDUK, SENTINEL, SNOW DOME, STOKES and WARWICK #2. The THC product is responsible for the felt from cannabis and is connected to the immune system regulating, anti-inflammatory and pain relieving properties of medical marijuana. The CBD product is connected to the anti-inflammatory, pain relieving, anti-nausea, anti-anxiety and muscle relaxing functions of medical marijuana.